Clinical Trial Update: Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating vascular disrupting agents or STAT3 inhibition to enhance PD-1 blockade in metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Snippet

Sponsor: Australasian Gastro-Intestinal Trials Group | Conditions: Colorectal Cancer Metastatic | Phase 2 | Status: COMPLETED